A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays

Immunologic Tests Clinical Trial

Official title:

A Study in Adult Subjects With Chronic Hepatitis B Infection to Support the Development of Immunological Assays

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01098006
• Other study ID #: 113854
• Status: Completed
• Phase: N/A
• Start date: April 29, 2010
• Est. completion date: February 20, 2012

Study information

• Verified date: February 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to develop and characterize immunological assays on blood samples.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: February 20, 2012
• Est. primary completion date: February 20, 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Written informed consent obtained from the subject.

• Subjects who the investigator believes that they can and will comply with the requirements of the protocol.

• A male or female between, and including, 18 and 65 years of age at study start.

• Evidence of chronic hepatitis B infection as per medical record.

• Female subjects of non-childbearing potential may be enrolled in the study.

• Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 day prior to study start.

In addition to these general inclusion criteria, subjects should satisfy ALL specific criteria according to the specified group maximum 6 months prior to Visit 1 as per medical records:

Group A: Immune tolerant patients

• Viral load: > 2x107 IU/mL of HBV DNA

• HBeAg positive

• Normal levels of ALT according to lab range Group B: HBeAg positive chronic hepatitis B patients

• Viral load: > 2x104 IU/mL of HBV DNA

• HBeAg positive

• Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy Group C:

Healthy carriers

• Viral load: not exceeding 2x103 IU/mL of HBV DNA

• HBeAg negative

• Normal levels of ALT measured at least twice, at least 3 months apart, during the last 6 months Group D: HBeAg negative chronic hepatitis B patients

• Viral load: > 2x103 IU/mL of HBV DNA

• HBeAg negative

• Increased levels of ALT and/or evidence of chronic hepatitis on liver biopsy

Exclusion Criteria:

• Any hepatitis B specific treatment prior to blood sampling at Visit 1.

• Any known clinically significant anaemia or any other condition within 7 days prior to study entry (Visit 1) as per medical records that would preclude the drawing of blood as described in the protocol.

• Receipt of live attenuated vaccines within 30 days preceding the blood sampling at Visit 1 and the administration of a pandemic influenza vaccine within 21 days preceding the blood sampling at Visit 1.

• Receipt of blood products within 120 days prior to study entry (Visit 1).

• Receipt of immunoglobulins within 120 days prior to study entry (Visit 1).

• Receipt of interferon within 120 days prior to study entry (Visit 1).

• Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding study start, or planned use during the study period.

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).

• History of immunosuppressive or immune-mediated disorders including autoimmune diseases, human immunodeficiency virus (HIV) infection and hepatitis C infection, based on medical history and physical examination (no laboratory testing required).

• Pregnant or lactating female.

• History of malignancy (unless there has been surgical excision followed by a sufficient observation period, of at least 5 years, to give a reasonable assurance of sustained cure and which, in the estimate of the investigator, is not likely to recur during the study period).

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs (including chloroquine) within six months prior to the blood sampling at Visit 1 (for corticosteroids, this will mean prednisone =10 milligram/day (10 mg/day), or equivalent). Inhaled and topical steroids are allowed.

• History of type I or type II diabetes mellitus including cases controlled with diet alone (a subject with past gestational diabetes is eligible).

• History of major congenital defect.

• Subjects with a history of, or current, alcohol or substance abuse.

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Immunologic Tests

Intervention

Other:
• Blood withdrawal
A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Brussels
Belgium	GSK Investigational Site	Bruxelles

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Frequency of Cluster of Differentiation 4 (CD4) + Forkhead Box p3 (Foxp3) + Expressing CD45RA and/or Human Leucocyte Antigen DR Complex (HLA-DR) and/or Inducible T Cell Co-stimulator (ICOS) and/or PD1	The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3- Expressing CD45RA and/or HLADR and/or ICOS and/or PD1	The frequency was assessed based on the following range of markers: CD4, CD45RA, ICOS, HLA-DR, PD-1 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3+ Expressing CD45RA and/or Glucocorticoid-induced Tumor Necrosis Factor Receptor-related Protein (GITR) and/or Proliferation Marker Ki67	The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3- Expressing CD45RA and/or GITR and/or Ki67	The frequency was assessed based on the following range of markers: CD4, CD45RA, GITR, anti-Foxp3 and Ki67.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3+ Expressing CD45RA and/or, Chemokine (C-C Motif) Receptor 7 (CCR7) and/or CD62L	The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3- Expressing CD45RA and/or CCR7 and/or CD62L	The frequency was assessed based on the following range of markers: CD4, CD45RA, CCR7, CD62L and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3+ Expressing CD45RA and/or CD39 and/or Tumor Necrosis Factor Receptor 2 (TNFR2)	The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3- Expressing CD45RA and/or CD39 and/or TNFR2	The frequency was assessed based on the following range of markers: CD4, CD45RA, CD39, TNFR2 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3+ Expressing CD45RA and/or CTLA4 and/or OX40	The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of CD4+Foxp3- Expressing CD45RA and/or CTLA4 and/or OX40	The frequency was assessed based on the following range of markers: CD4, CD45RA, CTLA4, OX40 and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of HBs- and HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Fresh Samples	The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of HBs- and HBc-specific CD4+Foxp3- Expressing CD69 and/or LAP in Fresh Samples	The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Primary	Frequency of HBc-specific CD4+Foxp3+ Expressing CD69 and/or LAP in Frozen Samples	The frequency was assessed based on the following range of markers: CD4, CD69, LAP and anti-Foxp3.	At the time of the visit for each subject (i.e., Day 0)
Secondary	Frequency of CD4+ Expressing CD40-L and/or Interferon-gamma (IFNg) and/or Interleukin 2 (IL-2) and/or IL-17 in Fresh Samples	The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.; Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).	At the time of the visit for each subject (i.e., Day 0)
Secondary	Frequency of Cluster of Differentiation 8 (CD8+) Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Fresh Samples	The frequency was assessed based on the following range of markers: CD8, CD40-L, IFNg, IL-2 and IL-17.; Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).	At the time of the visit for each subject (i.e., Day 0)
Secondary	Frequency of CD4+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples	The frequency was assessed based on the following range of markers: CD4, CD40-L, IFNg, IL-2 and IL-17.; Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).	At the time of the visit for each subject (i.e., Day 0)
Secondary	Frequency of CD8+ Expressing CD40-L and/or IFNg and/or IL-2 and/or IL-17 in Frozen Samples	The frequency was assessed based on the following range of markers: CD8, CD40L, IFNg, IL-2 and IL-17.; Note: The precision of the measure (i.e., four decimals) of median and inter-quartile range is not sufficient to distinguish between the values median, lower and upper limits of inter-quartile range for some of the data presented within the table below (e.g., median=0.0001 and inter-quartile range=0.0001 to 0.0001).	At the time of the visit for each subject (i.e., Day 0)